Methods and uses of cell therapies engineered with chimeric antigen receptors targeting B cell maturation antigens

JP7876453B2Inactive Publication Date: 2026-06-19JUNO THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
JUNO THERAPEUTICS INC
Filing Date
2021-04-09
Publication Date
2026-06-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for treating diseases related to B cell maturation antigen (BCMA) expression, such as multiple myeloma, are limited, and there is a need for improved adoptive cell therapies that reduce toxicity associated with existing BCMA-targeted treatments.

Method used

Administering a combination therapy of interleukin-1 receptor antagonist (IL-1Ra) and engineered T cells expressing a chimeric antigen receptor (CAR) specific to BCMA, with IL-1Ra given either before or after the T cell administration to mitigate toxicity.

Benefits of technology

Reduces the severity and occurrence of toxicity, such as cytokine release syndrome, neurotoxicity, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis, in subjects receiving BCMA-targeted therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007876453000051
    Figure 0007876453000051
  • Figure 0007876453000052
    Figure 0007876453000052
  • Figure 0007876453000053
    Figure 0007876453000053
Patent Text Reader

Abstract

Methods and uses relating to adoptive cell therapy are provided, including the administration of a dose of cells, such as T cells, to treat diseases and conditions, including certain plasma cell malignancies. The cells express a recombinant receptor, such as a chimeric antigen receptor (CAR) specific for B-cell maturation antigen (BCMA). In some embodiments, the method is for treating a subject with multiple myeloma (MM). TIFF2023522857000052.tif121170
Need to check novelty before this filing date? Find Prior Art